- Oct 3, 2018
- 2,957
| TYPE | Research & Development |
| COUNTRY | South Korea |
| PROJECT | Influenza Virus Vaccine - ROKOHTA-H1N1 - Development Phase |
| PROJECT COST | 200,000,000.00 |
| COMPLETION DATE | 1/10/2021 |
| PROJECT INFORMATION | The previous theory and exploration phase conducted by the State-run Korean Vaccine Research Team at the Osong Health Technology Administration Complex has discovered three possible vaccines methods to developing the Influenza Vaccine. 1) Egg-based flu vaccine, Cell-based flu vaccine, and 3) Recombinant flu vaccine. The OHTA research team has decided to pursue an egg-based vaccine design and begin minor developments on an egg-based flu vaccine. These methods will be developed into feasible vaccines. The vaccine will use fertilized chicken eggs to counter the H1N1, H3N2, and B strain of the Influenza Vaccine. However, the vaccine has wide coverage to be effective against all variants aimed at the commonalities as opposed to specifications. The Influenza vaccines will be developed in patheogen-free eggs that are eleven or twelve days old. The top of the egg is disinfected by wiping it with alcohol and then the egg is candled to identify a non-veinous area in the allantoic cavity where a small hole is poked to serve as a pressure release. A second hole is made at the top of the egg, where the influenza virus is injected in the allantoic cavity, past the chorioallantoic membrane. The two holes are then sealed with melted paraffin and the inoculated eggs are incubated for 48 hours at 37 degrees Celsius. During incubation time, the virus replicates and newly replicated viruses are released into the allantoic fluid After the 48-hour incubation period, the top of the egg is cracked and the ten milliliters of allantoic fluid is removed, from which about fifteen micrograms of the flu vaccine can be obtained. At this point, the viruses have been weakened or killed and the viral antigen is purified and placed inside vials, syringes, or nasal sprayers. Done on a large-scale, this method is used to produce the flu vaccine for the human population. The OHTA facilities will be managed by the ROK Ministry of Science and Technology, at the existing complex capable of conducting this research. The development phase will be aimed at developing the actual vaccine, running initial tests, alterations, and complete both the MoST and Medical code of ethics and Scientific Process. The vaccine development will be monitored and funded accordingly with the budget of the ROK MoST and partner agencies. At the end of the development phase, at least 250,000 vaccines will be readied for use based on the results for beginning official clinical trials. Animals shall be used for the developmental phase of this program before approval for initial human testing and then a wider clinical trial. |
| PRIVATE / ENCRYPTED | No |
